U.S. market Closed. Opens in 2 hours 58 minutes

AUPH | Aurinia Pharmaceuticals Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for AUPH we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is very weak.

Valuation (19%)

Company Industry
P/E Ratio (TTM) -56.96 -20.30
PEG Ratio (TTM) -1.05 -5.71
P/S Ratio (TTM) 5.83 50.88
P/B Ratio (TTM) 3.31 29.28
P/FCF Ratio (TTM) 44.59 -8.95
Price to 5YR AVG Earnings Ratio -9.16 -6.52
Price to 5YR AVG FCF Ratio -15.53 -14.78

Profitability (0%)

Company Industry
ROA (TTM) -4.11% -18.85%
ROE (TTM) -6.05% 25.35%
Net Profit Margin (TTM) -10.23% -827.80%
ROIC 5YR AVG -51.27% -26.10%

Growth (50%)

4QTR AVG 3YR AVG 5YR AVG
EPS 491.38% -33.78% -5.33%
Revenue 6.62% 5,206.69% 3,168.98%
Net Income 488.60% -50.77% -16.84%
Cash Flow 44.68% -52.93% -10.26%

Health (39%)

Company Industry
Current Ratio (TTM) 5.60 6.09
Quick Ratio (TTM) 5.11 5.87
D/E Ratio (TTM) N/A 1.00
Interest Coverage (TTM) -4.06 -9.57
Piotroski F-Score 2 4
Altman Z-Score 3.49 13.84
LTL to 5YR AVG FCF -0.99 0.07
Shares Outstanding Growth 5YR AVG 11.38% 44.11%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙